Do not order in the absence of a positive/equivocal ELISA screening test. During first 4 weeks of clinical symptoms, order concurrent IgM Western blot test.
- Patient Preparation
- Serum separator tube.
- Specimen Preparation
- Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.1 mL)
- Storage/Transport Temperature
- Unacceptable Conditions
- CSF or plasma. Contaminated, heat-inactivated, hemolyzed, severely lipemic specimens.
- After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
A positive result indicates that the Western blot evaluation for Borrelia burgdorferi antibody is consistent with the presence of antibody produced by patients in response to infection by Borrelia burgdorferi and suggests the presence of Lyme disease. Although the test has been shown to have a high degree of reliability for diagnostic purposes, laboratory data should always be correlated with clinical findings.
Current CDC recommendations for the serological diagnosis of Lyme disease are to screen with a polyvalent ELISA test and confirm equivocals and positives with Western blot. Both IgM and IgG Western blots should be performed on samples obtained less than four weeks after appearance of erythema migrans. Only IgG Western blot is to be performed on samples greater than four weeks after disease onset. IgM Western blot in the chronic stage is not recommended and does not aid in the diagnosis of neuroborreliosis or chronic Lyme disease.
|Component Test Code*||Component Chart Name||LOINC|
|0050252||B. Burgdorferi, IgG WB||6320-6|
- Lyme Antibody
- Lyme Disease
- Lyme Disease IgG WB
- Lyme Disease IgG Western Blot